AstraZeneca PLC (AZN)vsEnbridge Inc (ENB)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
ENB
Enbridge Inc
$53.59
-0.74%
ENERGY · Cap: $116.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Enbridge Inc generates 8% more annual revenue ($65.19B vs $60.44B). AZN leads profitability with a 17.2% profit margin vs 11.5%. AZN appears more attractively valued with a PEG of 1.52. ENB earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy62
out of 100
Grade: C+
ENB
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+4.6%
Fair Value
$54.02
Current Price
$53.59
$0.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Earnings expanding 294.9% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ENB
The strongest argument for ENB centers on EPS Growth, Debt/Equity, Market Cap.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : ENB
The primary concerns for ENB are Piotroski F-Score, PEG Ratio, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a mature stock while ENB is a value play — different risk/reward profiles.
ENB carries more volatility with a beta of 0.79 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
ENB scores higher overall (63/100 vs 62/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Enbridge Inc
ENERGY · OIL & GAS MIDSTREAM · USA
Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?